Education
About Us
Working with TipRanks
Follow Us
Maravai Lifesciences Holdings (MRVI)
NASDAQ:MRVI
Earnings Data
Report Date
May 11, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.08Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a clear operational turnaround: management exceeded cost-savings targets (> $65M), returned to positive adjusted EBITDA in Q4, and provided constructive 2026 guidance (revenue growth and a materially positive adjusted EBITDA outlook). Product momentum (ModTail, GMP enzymes, mRNAbuilder, IVT kits) and Cygnus' strong margins were highlighted as durable strengths. Headwinds remain, including sizable GAAP losses driven by impairment and restructuring charges, continued full-year negative adjusted EBITDA in 2025, outstanding leverage, and order lumpiness that can produce volatility. Overall, the tone is optimistic about returning to sustained profitability in 2026 while acknowledging near-term balance-sheet and GAAP earnings challenges.Company Guidance
Full-Year Revenue and Q4 Performance
Full-year 2025 revenue of $185.7M (beat guidance by ~$0.7M). Q4 2025 revenue $49.9M; excluding $14.3M of high-volume CleanCap sales in Q4 2024, Q4 revenue grew 18% year-over-year.
Return to Positive Adjusted EBITDA
Company delivered positive adjusted EBITDA of $0.536M in Q4 2025 (first positive adjusted EBITDA in four quarters), an improvement of ~$11M sequentially from Q3 and versus negative $1.1M in Q4 2024.
Exceeded Cost Savings Target
Restructuring and cost actions exceeded prior target of >$50M annualized savings; management now estimates >$65M of annualized savings (captured ~$3M in Q3 and ~$8M in Q4).
Strong Cygnus Profitability and Growth
Cygnus Q4 revenue $15.3M (up 4% YoY); Q4 adjusted EBITDA $10.2M representing a 66.7% margin. Full-year Cygnus revenue $66M (+5% YoY) with adjusted EBITDA $44.2M (67% margin).
TriLink Underlying Growth (Ex-CleanCap)
TriLink Q4 revenue $34.6M (down 17% YoY overall; excluding $14.3M COVID CleanCap comp in Q4 2024, base TriLink revenue grew 25% YoY). TriLink Q4 adjusted EBITDA $0.936M.
Product and Commercial Traction
ModTail launched in H2 2025 generated >$0.5M in 2025 and has already exceeded that level in 2026 YTD bookings; mRNAbuilder platform has processed ~70 orders; new IVT kit received >100 orders in first weeks; GMP enzymes orders of >$1.2M in hand for 2026.
2026 Financial Guidance Indicates Turnaround
Guidance for 2026: revenue $200M–$210M (growth 8%–13%); expected full-year adjusted EBITDA $18M–$20M (improvement of ~$50M–$52M vs 2025); projected ~1,200 bps gross margin expansion and operating expense reductions (OpEx -13%, G&A -18%).
Balance Sheet and Debt Reduction Action
Year-end cash $216.9M and long-term debt $294.2M. Company made a voluntary $50M debt repayment in Q1 2026, reducing both cash and debt to lower interest expense.
Corporate and Legal Risk Remediation
Completed implementation of internal controls remediation for previously identified material weaknesses; U.S. District Court dismissed securities class action lawsuits in full.
MRVI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MRVI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $3.26 | $3.56 | +9.20% |
Nov 06, 2025 | $2.89 | $2.87 | -0.69% |
Aug 11, 2025 | $2.06 | $2.69 | +30.58% |
May 12, 2025 | $2.12 | $2.06 | -2.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Maravai Lifesciences Holdings (MRVI) report earnings?
Maravai Lifesciences Holdings (MRVI) is schdueled to report earning on May 11, 2026, After Close (Confirmed).
What is Maravai Lifesciences Holdings (MRVI) earnings time?
Maravai Lifesciences Holdings (MRVI) earnings time is at May 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MRVI EPS forecast?
MRVI EPS forecast for the fiscal quarter 2026 (Q1) is -0.05.